At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
MCI-186 +2 moredrug
Likely dose
MCI-186 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT/QTc Interval in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating MCI-186 and Placebo for Healthy Adult Subjects. Completed, enrolled 27 participants across 1 site.
Detailed Summary
To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adult Subjects
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
Primary CompletionOct 2018
Study CompletionOct 2018
First PostedJul 2019
TodayJul 2026
First PostedJul 23, 2019
Enrollment StartSep 18, 2018
Primary CompletionOct 20, 2018
Study CompletionOct 23, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.9 years ago
Interventions
MCI-186drug
A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
MCI-186drug
A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
Placebodrug
A single dose of 0.9% w/v saline over 60 min will be intravenously administered.